Avoro Capital Advisors Llc

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$10.16B
Q ending 2026-03-31
Prior quarter
$10.17B
Q ending 2025-12-31
Change
-0.1% QoQ · +58.7% YoY
Positions
32
reported holdings

Largest positions

All 32 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
United Therapeutics CorpUTHRShares$1.56B2.6M
Ascendis PharmaShares$1.16B5.1M
Madrigal Pharmaceuticals IncMDGLShares$951.8M1.8M
Krystal Biotech IncKRYSShares$746.3M2.9M
Argenx SeARGXShares$730.3M1.0M
Arrowhead Pharmaceuticals IncARWRShares$670.9M10.7M
Kymera Therapeutics IncKYMRShares$622.6M7.5M
Apellis Pharmaceuticals IncAPLSShares$491.7M12.2M
Centessa Pharmaceuticals Plc260Shares$454.0M11.4M
Celcuity IncCELCShares$385.2M3.4M
Xenon Pharmaceuticals IncXENEShares$336.0M5.8M
Structure Therapeutics IncGPCRShares$316.0M6.6M
Terns Pharmaceuticals Inc430Shares$300.2M5.7M
Vera Therapeutics IncVERAShares$236.9M5.9M
Revolution Medicines IncRVMDShares$228.0M2.3M
Cytokinetics IncCYTKShares$219.7M3.3M
Ocular Therapeutix IncOCULShares$104.3M12.3M
Damora Therapeutics IncDMRAShares$98.0M3.8M
Uniqure NvShares$97.4M6.0M
Taysha Gene Therapies IncTSHAShares$97.0M21.7M
Definium Therapeutics IncDFTXShares$94.5M5.0M
Soleno Therapeutics IncSLNOEURShares$77.0M2.3M
Alkermes PlcShares$42.4M1.2M
Septerna IncSEPNShares$32.1M1.3M
Viridian Therapeutics IncVRDNShares$29.3M1.5M
Gh Research PlcShares$25.3M1.8M
Avalo TherapeuticsAVTXShares$21.1M1.4M
Lexeo Therapeutics IncLXEOShares$10.8M1.9M
United Therapeutics CorpUTHRCall$10.3M380K
Whitehawk Therapeutics IncWHWKShares$9.8M2.8M
Mannkind CorpMNKDShares$5.4M2.2M
Celcuity IncCELCCall$3.0M200K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.